Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

Inclusion Criteria:

   - Male and female participants 18 years and older.

   - Known or suspected focal liver lesions based on medical history and previous
   laboratory and/or imaging examinations.

   - Severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73
   m^2) based on medical history and previous laboratory examinations, at least once,
   within the last 3 months prior to the Baseline Visit, or participants with an increase
   in serum creatinine ≥ 0.3 mg/dL within 48 hours or ≥ 50% within 7 days prior to the
   Baseline Visit.

Exclusion Criteria:

   - Participants with simple liver cysts only.

   - Any investigational drug or device within 6 weeks prior to the Baseline Visit.

   - Any magnetic resonance imaging (MRI) contrast media within 6 weeks prior to Baseline
   Visit or scheduled to receive any contrast medium before the last study visit.

   - Participants with severe hepatic impairment (according to Child-Pugh score C).

   - Participants scheduled for surgery before last study visit.

   - Participants with encephalopathy / neurodegenerative or acute neurological disorders.

   - Participants with hemochromatosis.